ZEPBOUND 15 MG/DOSE (60 MG/2.4 ML) KWIKPEN
FDA nonproprietary name: tirzepatide
For 2.4 mL
Pharmacies pay
$675.43 filed
2.4 × $281.42838 per ML
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$1,221.91 filed
2.4 × $509.1301 per ML, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
1.8× estimated
Medicare paid 1.8× what pharmacies pay.
Part D averages every strength and form sold under “Zepbound” / “Tirzepatide” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$781.74 estimated
$675.43 + $101.31 (15%) + $5.00 fee per fill = $781.74
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
ZEPBOUND 15 MG/DOSE (60 MG/2.4 ML) KWIKPEN is how the CMS NADAC file names this product. The FDA NDC Directory lists it as tirzepatide, under the trade name “Zepbound KwikPen”.
FDA gives its dosage form as injection, solution and its route as subcutaneous.
The labeler, the company named on the label, is Eli Lilly and Company.
FDA lists it under 2 Established Pharmacologic Classes: GLP-1 Receptor Agonist and Glucose-dependent Insulinotropic Polypeptide Receptor Agonist.
The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes); the FDA directory lists 1 of them.
NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $675.43 for 2.4 mL (2.4 × $281.42838 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.
What NADAC measures · NADAC explanation codes
All 2 NDCs
- 00002-3511-01 · not listed as a package in the FDA directory · $281.42838 per ML · eff. 2026-09-23 filed
- 00002-3511-11 · Eli Lilly and Company · $281.42838 per ML · eff. 2026-09-23 filed
Other strengths, forms and brands
17 other products in the NADAC file share the FDA nonproprietary name tirzepatide with ZEPBOUND 15 MG/DOSE (60 MG/2.4 ML) KWIKPEN.
| Product | Pharmacies pay per unit | Medicare per unit |
|---|---|---|
| MOUNJARO 2.5 MG/0.5 ML PEN | $538.68839 per ML filed | $511.63411 per ML filed |
| MOUNJARO 5 MG/0.5 ML PEN | $538.63384 per ML filed | $511.63411 per ML filed |
| MOUNJARO 7.5 MG/0.5 ML PEN | $538.68042 per ML filed | $511.63411 per ML filed |
| MOUNJARO 10 MG/0.5 ML PEN | $538.68356 per ML filed | $511.63411 per ML filed |
| MOUNJARO 12.5 MG/0.5 ML PEN | $538.52518 per ML filed | $511.63411 per ML filed |
| MOUNJARO 15 MG/0.5 ML PEN | $538.51759 per ML filed | $511.63411 per ML filed |
| ZEPBOUND 2.5 MG/0.5 ML PEN | $526.20422 per ML filed | $509.1301 per ML filed |
| ZEPBOUND 2.5 MG/DOSE (10 MG/2.4 ML) KWIKPEN | $201.2566 per ML filed | $509.1301 per ML filed |
| ZEPBOUND 5 MG/0.5 ML PEN | $526.08276 per ML filed | $509.1301 per ML filed |
| ZEPBOUND 5 MG/DOSE (20 MG/2.4 ML) KWIKPEN | $201.03732 per ML filed | $509.1301 per ML filed |
| ZEPBOUND 7.5 MG/0.5 ML PEN | $526.00415 per ML filed | $509.1301 per ML filed |
| ZEPBOUND 7.5 MG/DOSE (30 MG/2.4 ML) KWIKPEN | $200.9187 per ML filed | $509.1301 per ML filed |
| ZEPBOUND 10 MG/0.5 ML PEN | $526.04607 per ML filed | $509.1301 per ML filed |
| ZEPBOUND 10 MG/DOSE (40 MG/2.4 ML) KWIKPEN | $281.62145 per ML filed | $509.1301 per ML filed |
| ZEPBOUND 12.5 MG/0.5 ML PEN | $525.84865 per ML filed | $509.1301 per ML filed |
| ZEPBOUND 12.5 MG/DOSE (50 MG/2.4 ML) KWIKPEN | $281.98531 per ML filed | $509.1301 per ML filed |
| ZEPBOUND 15 MG/0.5 ML PEN | $525.92209 per ML filed | $509.1301 per ML filed |
| ZEPBOUND 15 MG/DOSE (60 MG/2.4 ML) KWIKPEN this page | $281.42838 per ML filed | $509.1301 per ML filed |
Part D is one average per brand and generic name, over every strength and form.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
Compared with its class
The middle of its 2 NDCs’ NADAC prices is $281.42838 per ML filed.
Of the 39 other products in FDA’s GLP-1 Receptor Agonist class priced per ML, 28 have a higher middle NADAC price and 11 a lower one. The one in the middle is WEGOVY 1.7 MG/0.75 ML PEN, at $435.55769 per ML filed (eff. 2026-09-23).
Of the 17 other products in FDA’s Glucose-dependent Insulinotropic Polypeptide Receptor Agonist class priced per ML, 14 have a higher middle NADAC price and 3 a lower one. The one in the middle is ZEPBOUND 10 MG/0.5 ML PEN, at $526.04607 per ML filed (eff. 2026-09-23).
Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What Medicare paid
Medicare Part D paid $1,221.91 for 2.4 mL, at an average of $509.1301 per ML in 2024 (2024-01-01 to 2024-12-31) for “Zepbound” and “Tirzepatide”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 353 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 2.4 mL? Is it lower than what I would pay through my insurance?
- How much is in the package I am getting? This page uses 2.4 mL; your package may hold a different amount.
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for ZEPBOUND 15 MG/DOSE (60 MG/2.4 ML) KWIKPEN labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Zepbound / Tirzepatide: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's ML. Joined on brand name.
- Why does this page start at 2.4 mL?
- NADAC prices this product per ML. The FDA NDC Directory’s package description gives 2.4 mL in one package for the 1 of this product’s 2 NDCs it lists (“1 SYRINGE in 1 CARTON (0002-3511-11) / 2.4 mL in 1 SYRINGE (0002-3511-01)”), so the card starts at one package: 2.4 ML. Change it to match your prescription.
Related pages
Its pharmacologic classes
Related in the same class
- TRULICITY 0.75 MG/0.5 ML PEN
- RYBELSUS 14 MG TABLET
- SOLIQUA 100 UNIT-33 MCG/ML PEN
- LIRAGLUTIDE 2-PAK 18 MG/3 ML
- XULTOPHY 100 UNIT-3.6 MG/ML PEN